
Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.

Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.
إسطنبول، تركيا – (ARAB NEWSWIRE) — بدأت شركة ANT Systems الزراعية المتخصصة في تكنولوجيا النانو…
California Walnut كما أظهر بحثٌ جديد أن تناول الجوز في وجبة الإفطار يمكن أن يحسّن…
Arab Newswire - Press release distribution to media in MENA/GCC Regions Newswire expands reach with…
News AI-driven drug discovery company Insilico Medicine raised approximately HKD 2.28 billion (more than US$290 million) in its initial public…
The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and…
"Section 232" national security levies won't apply to a wide array of drugs, meaning the "overall threat to the sector…
News Merge Labs has emerged from stealth with $252 million in funding to develop non-implantable brain–computer interfaces that use ultrasound…
Sign in to your account